Novartis Ag · SIX:NOVN
Novartis — Q3 2025 Earnings Presentation
79 slides from Novartis's earnings presentation, Oct 28, 2025
Slide 1: Q3 2025 Results
Content Click below to navigate through the document Company overview Financial review Q3 2025 Conclusions Appendix Results References Investor presentation October 28, 2025 Novartis Q3 Results | October 28, 2025 1
Slide 2: Disclaimer
Content Click below to navigate Disclaimer through the document Company overview Financial review This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be identified by words such as “anticip
Slide 3: Disclaimer: Additional information and where to find it
Content Click below to navigate Disclaimer through the document Company overview Financial review Additional information and Where to Find It Conclusions In connection with the spin-off or sale of SpinCo and the merger (the “Transactions”), Novartis, Avidity and SpinCo intend to file relevant docume
Slide 4: Company overview
Content Click below to navigate through the document Company overview Financial review Conclusions Company Appendix References Company overview overview Vas Narasimhan, M.D. Chief Executive Officer Vas Narasimhan, M.D. Chief Executive Officer Novartis Q3 Results | October 28, 2025 4
Slide 5: Solid sales and core operating income growth along with strong pipeline progress in Q3
Content Click below to navigate Novartis delivered solid sales and core1 operating income growth along with strong pipeline progress in Q3 through the document Company overview Financial review Conclusions Sales Core1 operating income Innovation highlights USD bn, % cc1 USD bn, % cc Rhapsido® FDA ap
Slide 6: Priority brands continued to drive robust growth
GROWTH Content Click below to navigate Priority brands continued to drive robust growth, allowing us to more than offset the impact of increasing generic erosion through the document Company overview Financial review Q3 sales Conclusions Sales Growth vs. PY Growth vs. PY USD million USD million cc A
Slide 7: Kisqali grew +68% cc in Q3
GROWTH Content Click below to navigate Kisqali® grew +68% cc in Q3, outpacing the market and CDK4/6 competition through the document Company overview Financial review Sales evolution US Total Brand NBRx1 US: +91% in Q3 vs. PY Conclusions USD m, % cc • mBC leader in both NBRx (48% share) and TRx (37%
Slide 8: Kisqali 5-year data demonstrates 28.4% reduction in risk of recurrence
INNOVATION Content Click below to navigate Kisqali® 5-year data demonstrates 28.4% reduction in risk of recurrence1 in the broadest population of eBC patients through the document Company overview Financial review NATALEE 5-year data Presented at ESMO Conclusions iDFS benefit across pre-specified su
Slide 9: Kesimpta grew +44% cc in Q3
GROWTH Content Click below to navigate Kesimpta® grew +44% cc in Q3, fueled by continued strong demand growth through the document Company overview Financial review Sales evolution US: +45% in Q3 Conclusions USD m, % cc • Robust TRx growth +21% vs. PY, outpacing MS and B-cell markets1 US Ex-US • Bro
Slide 10: Pluvicto grew +45% cc in Q3
GROWTH Content Click below to navigate Pluvicto® grew +45% cc in Q3, continuing strong momentum following US pre-taxane mCRPC approval through the document Company overview Financial review Sales evolution US growth driven by demand in the pre-taxane setting Conclusions USD m, % cc • Q3 sales grew +
Slide 11: PSMAddition demonstrated Pluvicto plus SOC reduced risk of progression or death
INNOVATION Content Click below to navigate PSMAddition demonstrated Pluvicto® plus SOC reduced the risk of progression or death vs. SOC alone for PSMA+ mHSPC patients by 28% through the document Company overview Financial review Primary endpoint – rPFS1 Presented at ESMO Conclusions • Primary endpoi
Slide 12: Leqvio grew +54% cc in Q3
GROWTH Content Click below to navigate Leqvio® grew +54% cc in Q3, on track for blockbuster status in 2025 through the document Company overview Financial review Sales evolution US: +45%, outpacing advanced lipid-lowering market1,2 Conclusions USD m, % cc • MOTRx +44% vs. PY (market +35%) US Ex-US •
Slide 13: Scemblix grew +95% cc in Q3
GROWTH Content Click below to navigate Scemblix® grew +95% cc in Q3, on track for blockbuster status as the most prescribed TKI1 by NBRx in US through the document Company overview Financial review Sales evolution US All LoT NBRx Share1 US: NBRx leadership across all lines Conclusions USD m, % cc Co
Slide 14: Cosentyx growth impacted by one-time effects in Q3
GROWTH Content Click below to navigate Cosentyx® growth impacted by one-time effects in Q3; remains on track for mid-single digit growth in FY 2025 through the document Company overview Financial review Sales evolution US: +1% vs. PY, +9% when adjusting for one-time RDs Conclusions USD m, % cc • #1
Slide 15: Renal portfolio gaining traction in US
GROWTH Content Click below to navigate Renal portfolio gaining traction in US; positive Fabhalta® eGFR data to support traditional FDA approval in IgAN through the document Company overview Financial review Continued steady growth in US and rollout ex-US1 Conclusions Appendix IgAN portfolio: NBRx vo
Slide 16: Rhapsido approved by FDA as only oral targeted BTK inhibitor for CSU
INNOVATION Content Click below to navigate Rhapsido® approved by FDA as the only oral, targeted BTK inhibitor for CSU, a key milestone for potential pipeline-in-a-pill through the document Company overview Financial review Conclusions Broad population Clean safety Oral administration Appendix Indica
Slide 17: Ianalumab positive Phase III studies in SjD
INNOVATION Content Click below to navigate Ianalumab positive Phase III studies first ever to demonstrate clinically meaningful benefit in SjD through the document Company overview Financial review Phase III NEPTUNUS 1 & 2 studies1 NEPTUNUS-1 NEPTUNUS-2 Conclusions 0! 0! Primary endpoint met in both
Slide 18: Key innovation milestones in 2025
INNOVATION Content Click below to navigate Key innovation milestones in 2025 through the document Company overview 2025 selected key events (expected) H1 2025 H2 2025 Status as of end Q3 Financial review Regulatory Atrasentan IgAN US US approval (Q2) Fabhalta® (iptacopan) C3G US, JP EU US, EU approv
Slide 19: Financial review and 2025 guidance
Content Click below to navigate through the document Company overview Financial review Conclusions Financial review Appendix Financial References review and 2025 guidance and 2025 guidance Harry Kirsch Chief Financial Officer Harry Kirsch Chief Financial Officer Novartis Q3 Results | October 28, 202
Slide 20: Q3 net sales and core operating income grew +7% cc
FINANCIAL PROFILE Content Click below to navigate Q3 net sales and core1 operating income grew +7% cc, reflecting the strength of our growth drivers and recent launches through the document Company overview Financial review Key figures1 Q3 Q3 Change vs. PY 9M 9M Change vs. PY Conclusions USD million
Slide 21: 9M free cash flow approaching FY 2024 level
FINANCIAL PROFILE Content Click below to navigate 9M free cash flow1 approaching the level we achieved in FY 2024 through the document Company overview Financial review Free Cash Flow1 Conclusions USD billion Appendix +26% 2025 growth driven References by higher core operating income 15.9 12.6 9M 20
Slide 22: Continuing our shareholder-friendly capital allocation strategy
FINANCIAL PROFILE Content Click below to navigate Continuing our shareholder-friendly capital allocation strategy through the document Company overview Financial review Investing in the business Returning capital to shareholders Conclusions Appendix Investments in organic business Consistently growi
Slide 23: Reaffirming 2025 FY sales and core operating income guidance
FINANCIAL PROFILE Content Click below to navigate Reaffirming 2025 FY sales and core1 operating income guidance through the document Company overview Financial review Expected, barring unforeseen events; growth vs. PY in cc1 Conclusions Appendix Net sales Core operating income References expected to
Slide 24: Strong underlying growth trends expected throughout 2025
FINANCIAL PROFILE Content Click below to navigate Strong underlying growth trends expected throughout 2025, with Q4 impacted by prior-year one-timers and US generics through the document Company overview Financial review 2025 growth vs. PY (cc1) Actual Simulation Conclusions Illustrative Appendix Ne
Slide 25: Expected currency impact for full year 2025 and 2026
FINANCIAL PROFILE Content Click below to navigate Expected currency impact for full year 2025 and 2026 through the document Company overview Financial review Currency impact vs. PY Conclusions %pts, assuming late-October exchange rates prevail in 2025 and 2026 Appendix FX impact on Net sales FX impa
Slide 26: Proposed acquisition of Avidity raises 2024-2029 sales CAGR
FINANCIAL PROFILE Content Click below to navigate Proposed acquisition of Avidity1 raises Novartis 2024-2029 sales CAGR from +5% to +6%, and bolsters mid-single digit long-term through the document Company overview Net sales Financial review Conclusions Illustrative, USD billion, % CAGR cc2 • Expect
Slide 27: Conclusions
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix References Conclusions Conclusions Vas Narasimhan, M.D. Chief Executive Officer Vas Narasimhan, M.D. Chief Executive Officer Novartis Q3 Results | October 28, 2025 27
Slide 28: Novartis delivered solid sales and core operating income
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Novartis delivered Priority brands Strong pipeline Reaffirmed FY solid sales and core1 continue to perform progress, with key 2025 guidance and References operating income well reflecting mile
Slide 29: Upcoming investor events
Content Click below to navigate Upcoming investor events through the document Company overview Financial review Conclusions Immunology Meet Novartis Appendix Pipeline Update Management References October 30, 2025 November 19-20, 2025 Virtual London, UK Novartis Q3 Results | October 28, 2025 29 Novar
Slide 30: Appendix
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials Abbreviations References Appendix Novartis Q3 Results | October 28, 2025 30
Slide 31: Our pipeline projects at a glance
INNOVATION Content Click below to navigate Our pipeline projects at a glance through the document Company overview Financial review Phase I/II Phase III Registration Total Conclusions Oncology 24 10 0 34 Appendix Solid tumors 20 5 0 25 Innovation: Pipeline overview Hematology 4 5 0 9 Financial perfo
Slide 32: Novartis pipeline in Phase I
INNOVATION Content Click below to navigate Novartis pipeline in Phase I 17 lead indications through the document Lead indication Company overview Oncology Neuroscience Code Name Mechanism Indication(s) Code Name Mechanism Indication(s) EDK060 EDK060 - Charcot-Marie-Tooth disease Solid tumors Financi
Slide 33: Novartis pipeline in Phase II
INNOVATION Content Click below to navigate Novartis pipeline in Phase II 17 lead indications through the document Lead indication Company overview Oncology Neuroscience Code Name Mechanism Indication(s) Code Name Mechanism Indication(s) Solid tumors HTT227 votoplam Huntingtin Modulator Huntington’s
Slide 34: Novartis pipeline in Phase III
INNOVATION Content Click below to navigate Novartis pipeline in Phase III 6 lead indications through the document Lead indication Company overview Oncology Neuroscience Code Name Mechanism Indication(s) Code Name Mechanism Indication(s) BAF312 Mayzent® S1P1,5 receptor modulator Multiple sclerosis, p
Slide 35: Novartis pipeline in registration
INNOVATION Content Click below to navigate Novartis pipeline in registration through the document Company overview Cardiovascular, Renal and Metabolic Code Name Mechanism Indication(s) KJX839 Leqvio® siRNA (regulation of LDL-C) Hyperlipidemia, pediatrics Financial review Neuroscience Conclusions Cod
Slide 36: Novartis submission schedule: New molecular entities
INNOVATION Content Click below to navigate Novartis submission schedule through the document New Molecular Entities: Lead and supplementary indications Company overview CRM Immunology Neuroscience Oncology Non-core TA project Financial review 2025 2026 2027 ≥2028 Conclusions Rhapsido® ianalumab abel
Slide 37: Novartis submission schedule: Existing brands
INNOVATION Content Click below to navigate Novartis submission schedule through the document Supplementary indications for existing brands Company overview CRM Immunology Neuroscience Oncology Non-core TA project Financial review 2025 2026 2027 ≥2028 Conclusions Leqvio® Cosentyx® Fabhalta® Fabhalta®
Slide 38: Net debt increased by USD 4.2bn
FINANCIAL PROFILE Content Click below to navigate Net debt1 increased by USD 4.2bn as strong FCF2 was more than offset by shareholder distributions and M&A through the document Company overview Financial review USD bn -4.2 Conclusions Appendix Innovation: Pipeline overview Financial performance Inno
Slide 39: Clinical Trials Update
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials Clinical Trials Update > C ardiovascular, Renal and Metabolic > I mmunology > N euroscience > O ncology > I n-ma
Slide 40: Cardiovascular, Renal and Metabolic
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials Cardiovascular, Renal and Metabolic > C ardiovascular, Renal and Metabolic > I mmunology > N euroscience > O nco
Slide 41: atrasentan - ETA receptor antagonist
Content atrasentan - ETA receptor antagonist Click below to navigate through the document Company overview NCT04573478 ALIGN (CHK01-01) Financial review Indication IgA nephropathy Phase Phase 3 Conclusions Patients 380 Primary Change in proteinuria Time Frame: Up to Week 24 or approximately 6 months
Slide 42: Fabhalta - CFB inhibitor
Content Fabhalta® - CFB inhibitor Fabhalta® - CFB inhibitor Click below to navigate through the document Company overview NCT04578834 APPLAUSE-IgAN (CLNP023A2301) NCT05755386 APPARENT (CLNP023B12302) Financial review Indication IgA nephropathy Indication Immune complex-mediated membranoproliferative
Slide 43: Leqvio - siRNA (regulation of LDL-C)
Content Leqvio® - siRNA (regulation of LDL-C) Leqvio® - siRNA (regulation of LDL-C) Click below to navigate through the document Company overview NCT03705234 ORION-4 (CKJX839B12301) NCT05030428 VICTORION-2P (CKJX839B12302) Financial review Indication Hypercholesterolemia inc. Heterozygous Familial H
Slide 44: Leqvio - siRNA (regulation of LDL-C)
Content Leqvio® - siRNA (regulation of LDL-C) Click below to navigate through the document Company overview NCT05739383 VICTORION-1P (CKJX839D12302) Financial review Indication CVRR (Primary prevention) Phase Phase 3 Conclusions Patients 14000 Primary Time to the first occurrence of 4P-MACE Appendix
Slide 45: LTP001 - SMURF1 Inhibitor
Content LTP001 - SMURF1 Inhibitor Click below to navigate through the document Company overview NCT06649110 (CLTP001A12202) Financial review Indication Pulmonary arterial hypertension Phase Phase 2 Conclusions Patients 232 Primary Part A- Number of participants with Adverse events (AEs) and Serious
Slide 46: pelacarsen - Antisense oligonucleotide targeting Lp(a)
Content pelacarsen - Antisense oligonucleotide (ASO) Click below to navigate targeting Lp(a) through the document Company overview NCT04023552 Lp(a)HORIZON (CTQJ230A12301) Financial review Indication Secondary prevention of cardiovascular events in patients with elevated levels of lipoprotein(a) Con
Slide 47: QCZ484
Content QCZ484 Click below to navigate through the document Company overview NCT06857955 (CQCZ484A12201) Financial review Indication Hypertension Phase Phase 2 Conclusions Patients 380 Primary Change from baseline at Month 3 in mean 24hr systolic blood pressure (SBP) by Appendix Outcome ambulatory b
Slide 48: zigakibart - Anti-APRIL
Content zigakibart - Anti-APRIL Click below to navigate through the document Company overview NCT05852938 BEYOND (CFUB523A12301) Financial review Indication IgA nephropathy Phase Phase 3 Conclusions Patients 350 Primary Change in proteinuria [ Time Frame: 40 weeks or approximately 9 months ] Appendi
Slide 49: Immunology
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials Immunology > C ardiovascular, Renal and Metabolic > I mmunology > N euroscience > O ncology > I n-market Brands
Slide 50: GHZ339
Content GHZ339 Click below to navigate through the document Company overview NCT06947993 (CADPT17A12201) Financial review Indication Atopic dermatitis Phase Phase 2 Conclusions Patients 224 Primary Outcome Change from baseline in the Eczema Area and Severity Index (EASI) score at Appendix Measures W
Slide 51: ianalumab - BAFF-R inhibitor
Content ianalumab - BAFF-R inhibitor, ADCC-mediated B-cell Click below to navigate depletor through the document Company overview NCT05126277 SIRIUS-LN (CVAY736K12301) Financial review Indication Lupus Nephritis Phase Phase 3 Conclusions Patients 420 Primary Outcome Frequency and percentage of parti
Slide 52: ianalumab - BAFF-R inhibitor
Content ianalumab - BAFF-R inhibitor, ADCC-mediated B-cell ianalumab - BAFF-R inhibitor, ADCC-mediated B-cell Click below to navigate depletor depletor through the document Company overview NCT05639114 SIRIUS-SLE 1 (CVAY736F12301) NCT05624749 SIRIUS-SLE 2 (CVAY736F12302) Financial review Indication
Slide 53: ianalumab - BAFF-R inhibitor
Content ianalumab - BAFF-R inhibitor, ADCC-mediated B-cell Click below to navigate depletor through the document Company overview NCT06470048 (CVAY736S12201) Financial review Indication Systemic sclerosis Phase Phase 2 Conclusions Patients 200 Primary 3/5 Revised Composite Response Index in Systemic
Slide 54: remibrutinib - BTK inhibitor
Content remibrutinib - BTK inhibitor Click below to navigate through the document Company overview NCT05976243 (CLOU064M12301) Financial review Indication Chronic inducible urticaria Phase Phase 3 Conclusions Patients 348 Primary 1. Proportion of participants with complete response in Total Fric Sco
Slide 55: remibrutinib - BTK inhibitor
Content remibrutinib - BTK inhibitor remibrutinib - BTK inhibitor Click below to navigate through the document Company overview NCT06799000 RECHARGE1 (CLOU064J12301) NCT06840392 RECHARGE2 (CLOU064J12302) Financial review Indication Hidradenitis suppurativa Indication Hidradenitis suppurativa Phase P
Slide 56: Neuroscience
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials Neuroscience > C ardiovascular, Renal and Metabolic > I mmunology > N euroscience > O ncology > I n-market Brand
Slide 57: Fabhalta - CFB inhibitor
Content Fabhalta® - CFB inhibitor Click below to navigate through the document Company overview NCT123456 APPRAISE (CLNP023Q12301) Financial review Indication Generalized Myasthenia Gravis Phase Phase 3 Conclusions Patients 146 Primary Change from baseline to Month 6 in Myasthenia Gravis Activity of
Slide 58: Kesimpta - anti-CD20
Content Kesimpta® - anti-CD20 Click below to navigate through the document Company overview NCT06869785 FILIOS (COMB157Q12301) Financial review Indication Multiple sclerosis new dosing regimen Phase Phase 3 Conclusions Patients 180 Primary Ofatumumab plasma pharmacokinetics - area under the curve, u
Slide 59: Mayzent - S1P1,5 receptor modulator
Content Mayzent® - S1P1,5 receptor modulator Click below to navigate through the document Company overview NCT04926818 NEOS (CBAF312D2301) Financial review Indication Multiple sclerosis, pediatrics Phase Phase 3 Conclusions Patients 120 Primary Annualized relapse rate (ARR) in target pediatric parti
Slide 60: remibrutinib - BTK inhibitor
Content remibrutinib - BTK inhibitor remibrutinib - BTK inhibitor Click below to navigate through the document Company overview NCT05147220 REMODEL-1 (CLOU064C12301) NCT05156281 REMODEL-2 (CLOU064C12302) Financial review Indication Multiple sclerosis Indication Multiple sclerosis Phase Phase 3 Phase
Slide 61: remibrutinib - BTK inhibitor
Content remibrutinib - BTK inhibitor Click below to navigate through the document Company overview NCT06744920 RELIEVE (CLOU064O12301) Financial review Indication Myasthenia Gravis Phase Phase 3 Conclusions Patients 180 Primary Change from baseline to Month 6 in Myasthenia Gravis Activity of Daily L
Slide 62: VHB937 - TREM2 stabilizer and activator
Content VHB937 - TREM2 stabilizer and activator Click below to navigate through the document Company overview NCT07094516 (CVHB937A12201) Financial review Indication Alzheimer's disease Phase Phase 2 Conclusions Patients 407 Primary Change from Baseline in the Clinical Dementia Rating scale - Sum of
Slide 63: Oncology
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials Oncology > C ardiovascular, Renal and Metabolic > I mmunology > N euroscience > O ncology > I n-market Brands &
Slide 64: 225Ac-PSMA-617 - Radioligand therapy target PSMA
Content 225Ac-PSMA-617 - Radioligand therapy target PSMA Click below to navigate through the document Company overview NCT06780670 AcTFirst (CAAA817B12301) Financial review Indication Metastatic castration-resistant prostate cancer Phase Phase 3 Conclusions Patients 605 Primary Radiographic Progress
Slide 65: ianalumab - BAFF-R inhibitor
Content ianalumab - BAFF-R inhibitor, ADCC-mediated B-cell ianalumab - BAFF-R inhibitor, ADCC-mediated B-cell Click below to navigate depletor depletor through the document Company overview NCT05653349 VAYHIT1 (CVAY736I12301) NCT05653219 VAYHIT2 (CVAY736Q12301) Financial review Indication 1L Immune
Slide 66: ianalumab - BAFF-R inhibitor
Content ianalumab - BAFF-R inhibitor, ADCC-mediated B-cell Click below to navigate depletor through the document Company overview NCT05648968 VAYHIA (CVAY736O12301) Financial review Indication Warm autoimmune hemolytic anemia Phase Phase 3 Conclusions Patients 90 Primary Binary variable indicating w
Slide 67: iptacopan - CFB inhibitor
Content iptacopan - CFB inhibitor Click below to navigate through the document Company overview NCT04889430 APPELHUS (CLNP023F12301) NCT05935215 APPRECIATE (CLNP023F12302) Financial review Indication Atypical haemolytic uraemic syndrome Indication Atypical haemolytic uraemic syndrome Phase Phase 3 P
Slide 68: Lutathera - Radioligand therapy target SSTR
Content Lutathera® - Radioligand therapy target SSTR Click below to navigate through the document Company overview NCT06784752 NETTER-3 (CAAA601A62301) Financial review Indication Gastroenteropancreatic neuroendocrine tumors Phase Phase 3 Conclusions Patients 240 Primary Progression Free Survival (P
Slide 69: luxdegalutamide - Androgen receptor protein degrader
Content luxdegalutamide - Androgen receptor protein degrader Click below to navigate through the document Company overview NCT07047118 (CJSB462B12201) NCT06991556 (CJSB462C12201) Financial review Indication Metastatic castration resistant prostate cancer Indication Metastatic hormonal sensitive pros
Slide 70: Pluvicto - Radioligand therapy target PSMA
Content Pluvicto® - Radioligand therapy target PSMA Click below to navigate through the document Company overview NCT04720157 PSMAddition (CAAA617C12301) Financial review Indication Metastatic hormone sensitive prostate cancer Phase Phase 3 Conclusions Patients 1126 Primary Radiographic Progression
Slide 71: Vijoice - PI3Ki
Content Vijoice® - PI3Ki Click below to navigate through the document Company overview NCT05948943 EPIK-L1 (CBYL719P12201) Financial review Indication Lymphatic Malformation Phase Phase 2/3 Conclusions Patients 230 Primary Outcome Stage 2: Radiological response rate at Week 24 of Stage 2 (adult and
Slide 72: In-market Brands & Global Health
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials In-market Brands & Global Health > C ardiovascular, Renal and Metabolic > I mmunology > N euroscience > O ncolog
Slide 73: cipargamin - PfATP4 inhibitor
Content cipargamin - PfATP4 inhibitor Click below to navigate through the document Company overview NCT04675931 KARISMA (CKAE609B12201) Financial review Indication Malaria severe Phase Phase 2 Conclusions Patients 252 Primary Percentage of participants achieving at least 90% reduction in Plasmodium
Slide 74: ganaplacide/lumefantrine - Non-artemisinin plasmodium falciparum inhibitor
Content ganaplacide/lumefantrine - Non-artemisinin Click below to navigate plasmodium falciparum inhibitor through the document Company overview NCT05842954 KALUMA (CKLU156A12301) Financial review Indication Malaria, uncomplicated Phase Phase 3 Conclusions Patients 1720 Primary PCR-corrected adequat
Slide 75: Rydapt - Multi-targeted kinase inhibitor
Content Rydapt® - Multi-targeted kinase inhibitor Click below to navigate through the document Company overview NCT03591510 (CPKC412A2218) Financial review Indication Acute myeloid leukemia, pediatrics Phase Phase 2 Conclusions Patients 20 Primary Occurrence of dose limiting toxicities Appendix Outc
Slide 76: Abbreviations
Content Click below to navigate Abbreviations through the document Abbreviation Full Form Abbreviation Full Form Company overview 1L First-line ITP Immune Thrombocytopenia AAV Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis IV Intravenous ACR American College of Rheumatology LN Lup
Slide 77: References 1 of 3
Content Click below to navigate References 1 of 3 through the document Company overview Financial review Kisqali® (slide 7 references) 1 IQVIA Market Sizing Monthly Report, Aug 2025, rolling 3 months; Data lag: ~ 2 months. Conclusions 2 Of CDK4/6 market, US rolling 3 months ending Aug 2025, IQVIA Br
Slide 78: References 2 of 3
Content Click below to navigate References 2 of 3 through the document Company overview Financial review PSMAddition (slide 11 references) 1 Novartis, data on file. Data cut-off: Jan 13, 2025. Conclusions 2 91/572 patients (15.6%) crossed over from the control arm (ARPI + ADT) to receive Pluvicto pl
Slide 79: References 3 of 3
Content Click below to navigate References 3 of 3 through the document Company overview Financial review Renal portfolio (slide 15 references) 1 Unless otherwise mentioned, all commercial metrics refer to US market. Conclusions 2 Komodo claims data Sep 2024 – Apr 2025. 3 MMIT data as of Sep 2025. Ap